FIELD: biology.
SUBSTANCE: disclosed is an isolated peptide having the ability to induce cytotoxic T lymphocytes (CTL) against the NEIL3 antigen in the presence of an antigen-presenting cell (APC), carrying HLA-A*240. In addition, disclosed are a coding polynucleotide, a vector, a pharmaceutical composition, methods of inducing APC and CTL, as well as recovered APC, exosome, a method for inducing an immune response against a malignant tumor expressing NEIL3, and using a peptide, APC or an exosome according to the present invention in producing a pharmaceutical composition.
EFFECT: this group of inventions can find further application in therapy of NEIL3 related diseases.
14 cl, 9 dwg, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST MALIGNANT CELL, ANTI-CANCER DRUG AND METHOD FOR TESTING MALIGNANT NEOPLASM | 2015 |
|
RU2753512C2 |
| VACCINE COMPOSITION FOR MALIGNANT TUMOR | 2013 |
|
RU2721574C2 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| ANTITUMOR AGENT AND A METHOD OF ITS EVALUATION | 2019 |
|
RU2803148C2 |
| IMMUNITY INDUCER | 2016 |
|
RU2758112C2 |
| HLA-A*1101-LIMITED PEPTIDE WT1 AND PHARMACEUTICAL COMPOSITION THAT CONTAINS IT | 2007 |
|
RU2481398C2 |
| PEPTIDE OBTAINED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER USING IT, IMMUNITY INDUCER AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2016 |
|
RU2714117C2 |
| PEPTIDE DERIVED FROM FOXM1, AND INCLUDING ITS VACCINE | 2016 |
|
RU2738418C2 |
| IMMUNITY INDUCER | 2017 |
|
RU2755542C2 |
| CHIMERIC ANTIBODY/T-CELL RECEPTOR STRUCTURES AND THEIR APPLICATIONS | 2016 |
|
RU2767209C2 |
